Registration is now closed.
World Congress on Thyroid Cancer 4.0
July 29 – August 1, 2021
Long-term Survival More Than 1 Year Based on the Multimodal Treatment for Anaplastic Thyroid Cancer
- Presentation Speakers / Moderators
Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies with a mean survival time of 6 months regardless of treatment. The aim of this study is to present 23 series of ATC with long-term survival more than 1year.
Methods: This retrospective study used the single center database system of Gangnam Severance Hospital. The management and outcomes of 23 patients with a definitive histological diagnosis of ATC were reviewed.
Results: Long-term survivors were 11 men and 12 women, with mean age of 58 years. Nine patients had distant metastases at the diagnosis. Surgical debulking or complete resection of tumor were done in 19 patients, chemotherapy was done in 15 patients, radiation therapy was done in 18 patients and tyrosine kinase inhibitor was applied in 6 patients. Median survival was 1,090 days, and the 2- and 3-year survival rate was 59.7% and 35.8%, respectively. Ten patients were dead, 3 with local disease and 7 with distant metastasis
Discussion & Conclusions: Anaplastic thyroid cancer can be cured, and multimodality treatment including surgical resection, chemotherapy, radiotherapy and tyrosine kinase inhibitor can induce long-term survival more than 1 year.
Two Approaches to Level 5 Neck Dissection
- Jeff Blumberg